The Case for Globus Medical

The Setup

Globus Medical develops and sells the hardware of spine and musculoskeletal surgery: the pedicle screws, rods, plates, and intervertebral spacers that hold a repaired spine together, the trauma and joint-reconstruction implants that rebuild broken bones, and the navigation and robotics systems that guide the surgeon placing them. It is a business measured in procedures, not headlines, and it is a large one. The global spine market is worth well over ten billion dollars a year, and after its merger with NuVasive, Globus Medical is the number two player in it.

For most of the past year, the market has treated the stock with suspicion. Investors worried about integrating two large acquisitions, about whether the growth would hold, and about a falling return on invested capital as the deals were absorbed. The shares pulled back roughly 20% from their high to around $80. Meanwhile, the actual results kept improving. That gap, between a deteriorating narrative and improving numbers, is the setup.

This article will be direct about what Globus Medical is and is not. It is not one of the fortress-quality, wide-moat compounders that have anchored earlier theses in this series; its moat and balance-sheet scores are a clear step below those names. What it is, on the data, is a fast-growing, cash-generative medical device company whose merger is now producing real operating leverage, available at roughly 17 times earnings and a wide discount to fair value. The case is growth at a reasonable price, and the risks that keep it reasonable get a full section rather than a footnote.

The Merger Math

The transformation began with NuVasive. Globus Medical, long a scrappy, engineering-driven spine company, merged with NuVasive to create a combined business that vaulted it into the top tier of the global spine market, second only to Medtronic. It then added Nevro, a maker of spinal cord stimulation systems for chronic pain, extending its reach into neuromodulation. The strategic logic was scale: in a market where hospitals and surgeons prefer to consolidate their purchasing with fewer, broader partners, being a large full-line supplier is an advantage a niche player cannot match.

The execution is what matters, and here Globus Medical has delivered better than the skeptics feared. Management has said the integration exceeded its synergy targets and accelerated earnings accretion, and it did so with minimal sales disruption, the thing that most often goes wrong when two sales forces with overlapping surgeon relationships are combined. The combined company grew its base business at double-digit rates through the integration rather than stalling, which is the tell that the merger is working. The one soft spot, Nevro, is a smaller acquired business that has been weaker and is expected to recover in the second half of 2026, and the risk section returns to it.

The Operating Leverage

The first quarter of 2026 is the clearest picture of what the combined company can do. Revenue rose 27% year over year to $759.9 million, ahead of expectations, with organic growth above 13%. But the story is in the margins. Adjusted earnings per share jumped 65% to $1.12, far faster than revenue, because operating income grew 55% to $150.4 million and the operating margin expanded by 358 basis points to nearly 20%. Adjusted gross margin reached about 69% and adjusted EBITDA margin about 32%.

Earnings growing more than twice as fast as revenue is the signature of operating leverage, and it is coming from concrete sources: common systems rolling out across the merged company, production being brought in-house, and the fixed costs of the combined platform spreading over a larger revenue base. That leverage is showing up in cash. Free cash flow for 2025 came in near $589 million, up roughly 150%, and the company has used its cash to repurchase stock, more than $750 million deployed on buybacks since 2020, while still funding its growth. For 2026, management reaffirmed revenue guidance and raised its non-GAAP earnings outlook, a combination that says the margin expansion has further to run.

The Robotics Angle

The part of Globus Medical that could re-rate the whole company is its enabling technologies business, built around the ExcelsiusGPS robotic guidance and navigation platform and its extensions: Excelsius3D for imaging, ExcelsiusHub for real-time monitoring, and ExcelsiusFlex for robotic knee replacement. This segment posted its best quarterly revenue on record recently, and it matters for a reason beyond its own growth rate. A surgical robot is a razor, and the implants and disposables that flow through it for years afterward are the blades.

When a hospital installs an ExcelsiusGPS system, it creates a durable pull-through of Globus Medical implants for every procedure performed on that robot, and it raises the switching cost of moving to a competitor, because surgeons trained on one system do not casually relearn another. Robotics adoption in spine is still early, which means the installed base is a compounding annuity in the making rather than a mature one. As the enabling technologies footprint grows, it both drives high-margin recurring revenue and deepens the company's hold on the operating room. That is the growth engine the platform's backward-looking valuation does not fully credit.

The Moat

Honesty requires acknowledging that the platform scores Globus Medical's moat at 9 out of 15, moderate, well below the near-perfect readings of the Elite names in this series. That is the correct assessment. Spine and orthopedics is a genuinely competitive market, and Globus Medical shares it with giants: Medtronic, Stryker, Johnson & Johnson's DePuy Synthes, and Zimmer Biomet, several of them far larger and better-capitalized. This is not a company with a structural monopoly on its niche.

What moat it does have is real, though, and worth naming precisely. It comes from surgeon relationships and training, which are sticky because a surgeon who has standardized on a system and its instruments does not switch lightly; from the installed robotics base and the pull-through it creates; and from the scale and full-line breadth the merger delivered, which matters as hospital purchasing consolidates. That is a moat of switching costs and scale rather than of untouchable technology, and it is enough to defend share and earn good margins, which the results confirm. It is simply not the fortress that a 14-out-of-15 moat score would imply, and the thesis does not pretend otherwise.

What the Wealth Engine Scores Say

Before we get to the valuation argument, here is what the Wealth Engine Pro platform's systematic scoring shows for this stock right now.

The scores tell a coherent and honest story. The standout is Growth at 14 out of 15, which captures the revenue and earnings acceleration described above, paired with the largest Fair Value discount of any stock in this series, roughly 29% below the platform's $104.27 estimate. Just as important is what the scores hold back: a Company Strength of 68 that is Strong but not Elite, a Financial Health of 65 that reflects an acquisitive, more leveraged balance sheet, and a Moat of 9. This is a quality tier below the recent fortress names, and the platform says so plainly.

These scores are systematic. They evaluate companies based on reported financials, balance sheet quality, moat characteristics, and valuation models (DCF, peer comparison, earnings power). They measure what a company is today, not what it might become. That is by design: the scoring system is built to keep emotion and forward speculation out of the numbers.

The editorial argument adds the forward view, that the operating leverage still has room to run and that robotics adoption is a compounding pull-through the model cannot yet price. But the discount does not require heroic assumptions to be interesting; even scored purely on today's reported growth and cash flow, the model calls the stock meaningfully undervalued. The honest reading is that this is a high-growth business at a discounted price and a moderate quality grade, and the buyer is trading some of the fortress quality of earlier picks for a faster grower at a bigger discount.

The Valuation Case

At around $80, against management's raised 2026 non-GAAP earnings guidance of roughly $4.70 to $4.80, Globus Medical trades near 17 times forward earnings. For a company growing revenue in the double digits, growing earnings far faster on operating leverage, and generating strong free cash flow, that is a modest multiple. The platform's fair value of $104.27 implies about 29% upside, and Wall Street sits in the same neighborhood or higher, with Overweight ratings and price targets in the $103 to $123 range. The systematic model, the analysts, and the editorial view converge on the same conclusion: the stock is cheaper than the business.

The discount exists because the market is discounting execution. Investors have watched medical device companies stumble on big acquisitions before, and they are pricing in the possibility that the integration falters, that the return on capital keeps sliding, or that the growth was pulled forward. Those are legitimate concerns, addressed next. But the pattern so far, beat-and-raise quarters, expanding margins, and rising cash flow, argues that the skepticism has overshot. A 17-times multiple leaves room for the stock to re-rate simply by the company continuing to do what it has been doing.

What Could Go Wrong

The most cited concern is the return on invested capital. Globus Medical funded its transformation with large acquisitions, and as that capital sits on the balance sheet, its return on invested capital has been declining. If the acquired businesses do not earn back their cost of capital, the growth becomes far less valuable, and the bull case, which assumes the merged company compounds efficiently, weakens. This is the single metric that most threatens the thesis, and it deserves to be watched quarter by quarter.

The second risk is integration, and specifically Nevro. The spinal cord stimulation business Globus Medical acquired has been the weak link, and the thesis leans on a second-half-2026 recovery that has not yet been proven. If that recovery stalls, or if the core spine integration develops sales dissynergies that have so far been avoided, the growth rate that justifies the valuation could slow abruptly.

Third is the nature of the enabling-technologies business itself. High-ticket robotic systems sell in lumpy, capital-budget-driven cycles, so a quarter or two of soft hospital spending can make the growth look worse than the underlying trend. And the competitive reality is unavoidable: Globus Medical is fighting Medtronic, Stryker, Johnson & Johnson, and Zimmer Biomet, any of which can out-spend it on research or discount aggressively to defend share.

Finally, the scores themselves are the caution. A Moat of 9 and a Financial Health of 65 mean this is a genuine step down in quality from the fortress names, with less balance-sheet cushion if something goes wrong, and the platform's outlook signal, while Bullish today, has been less consistent than for those names. The platform rates Globus Medical Bullish and Undervalued, but this is a faster grower carrying more execution and quality risk, and that is the honest tradeoff a buyer accepts here.

The Thesis

Globus Medical is the number two company in global spine, growing revenue 27% and adjusted earnings 65% last quarter while expanding margins and generating record free cash flow, and it trades near 17 times earnings and roughly 29% below the platform's fair value. The systematic model, the analyst community, and the editorial view all point to the same gap between price and value. The engine is real: merger scale producing operating leverage, and a growing installed base of surgical robots pulling through high-margin recurring revenue.

The thesis is deliberately framed as growth at a reasonable price, not as fortress quality. This is a Strong company, not an Elite one; its moat is moderate, its balance sheet is more leveraged than the fortress names, and its returns on capital bear watching. What it offers in exchange is a faster growth rate and a wider discount, and the honest question for a buyer is whether the execution that has driven the recent beat-and-raise quarters continues. The data so far says it is, and the risks that could change that are laid out in full above.

This is how the Wealth Engine Pro philosophy is meant to work. The platform did not overstate the case; it scored the business a strong grower at a large discount and, in the very same numbers, flagged the moderate moat and health that mark it a tier below the fortress names. The editorial view adds the operating-leverage and robotics story and weighs it against the integration and capital-efficiency risks. The data and the analysis agree on the opportunity and on its price. They are equally clear that this is a faster, riskier grower rather than a fortress, and saying so is the point.